Understanding Caregiver Goals, Benefits, and Acceptable Risks of Peanut Allergy Therapies

Peanut allergy affects 1.4-4.5% of children and may be a lifelong allergy in 75%.1 Nearly 50% of peanut allergic individuals have had a past severe reaction.2 Several promising peanut allergy treatments are under development.3 Peanut allergy is associated with anxiety and poor quality of life (QoL) in the child and caregiver, driven by fear the child will react from an accidental exposure—something treatment could prevent.4–10 For these reasons, two therapies, peanut oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT), have been granted US Food and Drug Administration (FDA) fast-track status.

https://ift.tt/2ttcCVh